GLP-1 and Dental Sedation: Do You Stop First? (2026)

If you take Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 and you have dental IV sedation, deep sedation, or general anesthesia scheduled — wisdom teeth, implants, a long restorative visit — the question you're searching is whether you have to stop the drug first. The honest answer is: it depends on how deep the sedation is, and you should not decide it yourself. GLP-1 drugs slow how fast the stomach empties, so it can still hold food and fluid after normal fasting — which raises a theoretical risk of regurgitating and aspirating into the lungs while sedated. In June 2023 the American Society of Anesthesiologists (ASA) advised holding GLP-1s before procedures requiring anesthesia; a 2024 multisociety update softened that to risk-stratified, shared decision-making (Kindel 2025 ^[3]). Crucially, most dental work uses minimal or moderate sedation, where your protective airway reflexes stay intact and the aspiration concern is much lower — the worry concentrates in deep sedation and general anesthesia (McKenzie 2025 ^[1]). This article walks through that distinction. For the general surgery version see holding a GLP-1 before surgery, and for the endoscopy version see GLP-1 before a colonoscopy.

The honest summary

• The level of sedation matters most. Aspiration risk is tied to losing protective airway reflexes. Minimal sedation (e.g., nitrous oxide, oral anxiolytics) and moderate (“conscious”) sedation generally preserve those reflexes; deep sedation and general anesthesia do not — which is where a fuller stomach becomes dangerous (McKenzie 2025^[1]).
• The concern is real for deep IV sedation/GA. Dental case reports describe patients on semaglutide with solid stomach contents despite fasting well beyond the usual window, and pulmonary aspiration is among the top airway adverse events in office-based anesthesia (McKenzie 2025^[1]).
• ASA said hold it (June 2023). The anesthesiologists' consensus advised skipping the dose on the day of the procedure for daily-dosed GLP-1s and stopping weekly-dosed ones (Ozempic, Wegovy, Mounjaro, Zepbound) about a week before any procedure requiring anesthesia (McKenzie 2025^[1]; Hashash 2024^[2]).
• The 2024 multisociety update relaxed it. Most patients can continue their GLP-1; hold decisions should be risk-stratified and shared between the sedation provider, prescriber, and patient — with a clear-liquid diet for 24 hours before for higher-risk cases (Kindel 2025^[3]).
• Dental-specific data are thin. Almost everything for the dental chair is extrapolated from surgical and endoscopy evidence; there is no large dental aspiration outcome study, so guidance leans on the broader perioperative literature (Khan 2025^[4]; Chang 2024^[9]).
• Bottom line: don't stop on your own. Tell BOTH your dentist/oral surgeon (and their anesthesia provider) AND your prescriber. The plan depends on the drug, your dose, your symptoms, and — above all — how deep the planned sedation is.

Why dental sedation raises the question at all

GLP-1 receptor agonists slow how fast the stomach empties — that delayed emptying is part of how they reduce appetite. The side effect that matters here is that your stomach can still contain solids or fluid even after you've followed the usual “nothing to eat” fasting instructions. When someone is sedated deeply enough that their protective airway reflexes are blunted, retained stomach contents can be regurgitated and aspirated into the lungs — a rare but potentially devastating event. A dentistry-focused review noted that pulmonary aspiration is among the top three airway adverse events in office-based anesthesia, and cited a case of a patient on semaglutide who had solid gastric contents despite fasting from solids for more than 18 hours (McKenzie 2025^[1]).

The hard signal that GLP-1s leave more in the stomach comes from outside dentistry. Silveira 2023^[5], a retrospective study of 404 patients having upper endoscopy, found that semaglutide users had retained gastric contents 24.2% of the time versus 5.1% of non-users — an adjusted odds ratio around 5.2 — even though most had stopped the drug roughly 10 days earlier. A prospective gastric-ultrasound study in volunteers showed the same direction of effect (Sherwin 2023^[6]). Whether that “food in the stomach” finding translates into actual lung injury is far less certain: a scoping review concluded the evidence linking GLP-1 use to real regurgitation or aspiration events (as opposed to retained contents on imaging) is limited and mixed (Chang 2024^[9]). A large pooled analysis of GI-endoscopy patients makes the same point quantitatively: GLP-1 users had roughly 4.5× the odds of retained gastric contents, yet no significant increase in aspiration pneumonia (Baig 2025^[8]). That gap — clear effect on stomach contents, unclear effect on aspiration — is exactly why the specialties disagreed about how aggressively to hold the drug.

What the guidance actually says

In June 2023 the American Society of Anesthesiologists issued consensus-based guidance recommending that patients hold their GLP-1 before elective procedures requiring anesthesia: skip the dose on the day of the procedure for daily-dosed agents, and stop weekly-dosed agents (semaglutide as Ozempic/Wegovy, tirzepatide as Mounjaro/Zepbound) about a week beforehand. That guidance was written for the operating room, but because office-based dental sedation and general anesthesia carry the same airway concerns, dental-anesthesia providers adopted it (McKenzie 2025^[1]; Hashash 2024^[2]).

The 2024 multisociety guidance — written jointly by anesthesiology, gastroenterology, and bariatric-surgery groups — relaxed the blanket hold in favor of risk stratification and shared decision-making (Kindel 2025^[3]). Its framing, as applied to dentistry: lower-risk patients can generally continue the GLP-1, while higher-risk patients warrant balancing the benefit of the drug against aspiration risk. You're treated as higher risk if you're in the dose-escalation phase, on a higher dose, on weekly (vs daily oral) dosing, or have ongoing GI symptoms — and lower risk in the maintenance phase, on a lower dose, or on daily oral dosing. For higher-risk patients it offered a middle path: a clear-liquid diet for 24 hours before, and/or point-of-care gastric ultrasound on the day. Notably, the ASA itself acknowledged that no evidence supports an optimal fasting duration for GLP-1 users — a candid admission that the hold timing is consensus, not data (McKenzie 2025^[1]).

Two dentistry-specific reviews translate this to the chair. A British Dental Journal piece on caring for dental patients on GLP-1s or tirzepatide requiring sedation, and a longer review in Anesthesia Progress, both stress an individualized, symptom-screening approach over reflexive cancellation (Khan 2025^[4]; McKenzie 2025^[1]). The honest caveat in both: there is no large dental study of aspiration outcomes in GLP-1 patients. The recommendations are extrapolated from surgical and endoscopy data, so they carry real uncertainty — which is part of why a conservative default (lighter sedation, or deferring deep sedation when unsure) is reasonable. Even among anesthesiologists, practice varies: a national survey found wide disagreement on whether and how long to hold GLP-1s before elective procedures, reflecting how much of this rests on consensus rather than hard outcome data (Boudreau 2025^[10]).

What this means for your appointment — the practical upshot

• Ask how deep the sedation will be. Nitrous oxide or a single oral pill (minimal sedation) is a very different aspiration picture than IV deep sedation or general anesthesia. The level of sedation largely determines whether the GLP-1 question even applies (McKenzie 2025^[1]).
• Don't stop your GLP-1 on your own. The right plan depends on the drug, your dose schedule, your symptoms, and the facility's protocol. Self-discontinuing can also worsen diabetes blood-sugar control.
• Tell BOTH your dental/oral-surgery team AND your prescriber, well ahead. Name the exact drug (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, etc.), your dose, and when you last took it. Ask directly: should I hold a dose, and should I extend my clear-liquid diet?
• Flag any ongoing GI symptoms. Nausea, vomiting, bloating, reflux, or feeling full are the strongest predictors of retained stomach contents (Silveira 2023^[5]; Santos 2024^[7]). If you have them near your appointment, say so — it may change the plan or push toward lighter sedation.
• Expect a possible extended clear-liquid diet for deeper sedation. Higher-risk patients are often asked to do at least 24 hours of clear liquids beforehand (Kindel 2025^[3]).
• Follow YOUR facility's written instructions. Dental-anesthesia protocols genuinely differ between offices; the consensus documents leave room for local judgment. Your provider's pre-sedation sheet is the one that counts.

Does a one-week hold even empty the stomach?

Not necessarily — and this is a genuine limitation of the ASA timing. In Santos 2024^[7], among semaglutide users having upper endoscopy, stopping the drug for fewer than 8 days still left a roughly 10-fold higher chance of retained stomach contents, and 8–14 days a ~4.6-fold higher chance; only stopping for more than 14 days (in people without ongoing GI symptoms) brought the risk in line with non-users. That undercuts the assumption that the ASA's one-week hold guarantees an empty stomach, and it's part of why some experts favor a thorough clear-liquid prep, symptom screening, and an appropriate sedation depth over relying on a hold alone. It also reinforces the central point: with imperfect tools, the safest plan for deep sedation is built with your providers, not improvised by you.

Bottom line

GLP-1 drugs do leave more food in the stomach despite fasting, which creates a real aspiration concern under deep dental sedation and general anesthesia — but much less so under minimal or moderate sedation, where your airway reflexes stay intact (McKenzie 2025^[1]). The ASA initially advised holding the drug before procedures requiring anesthesia (Hashash 2024^[2]); the 2024 multisociety update moved to risk-stratified, shared decision-making with a clear-liquid option for higher-risk patients (Kindel 2025^[3]), and a one-week hold may not even empty the stomach reliably (Santos 2024^[7]). Dental-specific outcome data are sparse, so the chair-side guidance is extrapolated (Khan 2025^[4]; Chang 2024^[9]). The single safest thing you can do is not decide alone: ask how deep the sedation will be, tell both your dental team and your prescriber which GLP-1 you take and when you last took it, ask about holding a dose and extending clear liquids, and follow your facility's written instructions.

This article is educational and is not medical or dental advice. Every claim above is sourced to a peer-reviewed study, society clinical practice update, or dentistry-specific review indexed in PubMed, verified against the live PubMed database (and, where open-access, the fulltext) before publication. Dental-specific aspiration outcome data are limited; much of this guidance is extrapolated from surgical and endoscopy evidence. Coordinate your own pre-sedation plan with your prescriber and your dental-anesthesia provider.